Table 1.
Immunohistochemical expression analysis of the CXCR4-CXCL12 axis in Ewing sarcoma
|
UPNa |
sample type (years after diagnosis) |
CXCR4b |
CXCL12 |
|
|---|---|---|---|---|
| tumor | stroma | |||
| 1 |
lung metastasis (3) |
- |
- |
+/− |
| |
bone metastasis (7) |
- |
- |
+/− |
| 2 |
lung metastasis (2) |
- |
+ |
+ |
| 3 |
therapy-naive biopsy |
+/− |
+ |
+ |
| |
lung metastasis (5,5) |
- |
- |
+/− |
| 4 |
therapy-naive biopsy |
++ |
+/− |
+ |
| |
lung metastasis (3) |
- |
+ |
++ |
| |
lung metastasis (4) |
- |
+ |
++ |
| 5 |
therapy-naive biopsy |
++ |
+/− |
++ |
| |
bone metastasis (1) |
n.e. |
+/− |
+ |
| 6 |
therapy-naive biopsy |
+ |
++ |
n.e. |
| |
lung metastasis (1) |
+/− |
+/− |
+/− |
| 7 |
therapy-naive biopsy |
++ |
++ |
+ |
| 8 |
therapy-naive biopsy |
++ |
+/− |
+ |
| |
bone metastasis (2,5) |
+ |
++ |
++ |
| 9 |
therapy-naive biopsy |
- |
+ |
+ |
| |
lung metastasis (0,5) |
+ |
+ |
++ |
| 10 |
therapy-naive biopsy |
+ |
- |
+/− |
| 11 |
therapy-naive biopsy |
- |
+ |
+/− |
| 12 |
therapy-naive biopsy |
+ |
+/− |
+ |
| 13 |
therapy-naive biopsy |
++ |
- |
+/− |
| 14 |
therapy-naive biopsy |
- |
+/− |
+ |
| 15 |
therapy-naive biopsy |
- |
- |
+/− |
| 16 |
therapy-naive biopsy |
- |
+ |
+/− |
| 17 |
therapy-naive biopsy |
- |
+ |
+ |
| 18 |
therapy-naive biopsy |
+ |
+/− |
+/− |
| 19 |
therapy-naive biopsy |
- |
+/− |
+ |
| 20 |
therapy-naive biopsy |
+/− |
- |
+ |
| 21 |
therapy-naive biopsy |
- |
- |
+/− |
| 22 |
therapy-naive biopsy |
- |
- |
- |
| 23 |
therapy-naive biopsy |
- |
+/− |
+/− |
| 24 |
therapy-naive biopsy |
+/− |
+/− |
+/− |
| 25 |
therapy-naive biopsy |
++ |
- |
- |
| 26 |
therapy-naive biopsy |
- |
+ |
+ |
| 27 |
therapy-naive biopsy |
+ |
+/− |
+ |
| 28 |
therapy-naive biopsy |
++ |
+/− |
+ |
| 29 |
therapy naive biopsy |
- |
- |
+/− |
| 30 |
therapy-naive biopsy |
++ |
++ |
+ |
| 31 |
therapy-naive biopsy |
+ |
- |
++ |
| 32 |
therapy-naive biopsy |
+ |
+ |
+ |
| 33 |
therapy-naive biopsy |
- |
- |
+/− |
| 34 |
therapy-naive biopsy |
++ |
+ |
+ |
| 35 |
therapy-naive biopsy |
+ |
- |
+/− |
| 36 |
therapy-naive biopsy |
+ |
+ |
+ |
| 37 |
therapy-naive biopsy |
+ |
- |
+ |
| 38 |
therapy-naive biopsy |
++ |
n.e. |
n.e. |
| 39 |
therapy-naive biopsy |
++ |
- |
+/− |
| 40 |
therapy-naive biopsy |
- |
- |
+/− |
| 41 |
therapy-naive biopsy |
+ |
+ |
+ |
| 42 |
therapy-naive biopsy |
+ |
- |
+/− |
| 43 |
therapy-naive biopsy |
- |
++ |
+ |
| 44 |
therapy-naive biopsy |
- |
+ |
+ |
| 45 |
lung metastasis (1,5) |
+/− |
+/− |
++ |
| |
bone metastasis (2,5) |
++ |
+/− |
+ |
| |
lung metastasis (2,5) |
- |
+ |
++ |
| |
lung metastasis (4) |
- |
+/− |
++ |
| |
lung metastasis (4) |
+/− |
+/− |
+ |
| |
lung metastasis (5) |
+ |
+ |
+ |
| 46 |
therapy-naive biopsy |
+ |
+ |
+ |
| 47 | therapy-naive biopsy | +/− | ++ | ++ |
aUPN = unique patient number. n.e. = not evaluable; - = absent expression; ‘+/− = weak expression; + = moderate expression; ++ = strong expression. bt-test: therapy-naive Ewing sarcoma demonstrated significantly higher CXCR4 expression levels as compared to metastatic lesions (p = 0.027).